Pricing Log in Create free account
Friday 6 November 2026 Export CRDF’s income statement to Excel — free account

Cardiff Oncology, Inc.

CRDF Healthcare Biotechnology

Cardiff Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $593,000.00, down 13.2% from fiscal 2024.

Revenue
−14.1%
EPS
+33.3%
Free cash flow
−41.4%

Quarter to June 2026, against a year earlier

0.78 0.02 +2.63%
Market cap
$58.8M
P/E
0.0×
Fwd P/E
−1.5×
Dividend yield
—
F-score
2/9
Altman Z
−4.65
Beneish M
−4.02
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 1.12
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — 2 2 — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 58.76
Revenue ttm 0.51
Net income ttm (40.05)
Free cash flow ttm (40.94)
Net debt Q (34.52)
Valuation
P/E 0.00
Forward P/E (1.49) (negative: loss-making)
Price / sales 105.02 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 2.01
Financial health
Current ratio Q 3.30 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (10.13)
Growth
Revenue growth Q −14.05% (below 0%: shrinking)
Operating income growth Q +34.93% (above 0%: growing)
EPS, this year +16.31% (at or above 15%: strong)
EPS, next year A −5.38% (below 0%: weak)
Revenue, next year A −50.24% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A −8.14% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 39.8×, against a ten-year median of 69.1×; over the ten years it ranged from −194× in 2022 to 1,593× in 2020.
P/S against its own 10 years 29.95%
10-year low 10-year high
P/B against its own 10 years 47.65%
10-year low 10-year high
EV/Sales against its own 10 years 25.38%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 75 92 58 35
Receivables 0 1 0 0
Inventory — — — —
Other — — — —
77 95 60 36
2023 2024 2025 Q'26
Payables 2 5 8 4
ST’ Debt — — — —
Other — — — —
10 13 16 11

Compound Annual Growth %

10y 5y 3y
Sales 6.61% 10.13% 15.39%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (0.70%) (18.75%) (24.71%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.17 Actual −0.14

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.20 −0.17 Beat by 0.03
Q4 FY25 −0.18 −0.11 Beat by 0.07
Q1 FY26 −0.13 −0.18 Miss by 0.05
Q2 FY26 −0.17 −0.14 Beat by 0.03
Q3 FY26 −0.14 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.18) (0.14) — — —
’25 (0.20) (0.21) (0.17) (0.11) (0.69)
’24 (0.22) (0.26) (0.25) (0.21) (0.95)
’23 (0.25) (0.25) (0.22) (0.21) (0.93)
’22 (0.25) (0.24) (0.20) (0.20) (0.89)
’21 (0.14) (0.17) (0.17) (0.23) (0.73)
’20 (0.41) (0.51) (0.19) (0.19) (1.08)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 0 0 0 1
’24 0 0 0 0 1
’23 0 0 0 0 0
’22 0 0 0 0 0
’21 0 0 0 0 0
’20 0 0 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) (12) — — —
’25 (13) (8) (11) (6) (38)
’24 (8) (9) (10) (10) (38)
’23 (9) (7) (8) (7) (31)
’22 (10) (7) (7) (9) (34)
’21 (6) (4) (5) (7) (23)
’20 (3) (4) (4) (5) (16)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) (12) — — —
’25 (13) (8) (11) (6) (38)
’24 (8) (9) (10) (10) (38)
’23 (9) (7) (8) (7) (31)
’22 (10) (7) (8) (9) (35)
’21 (6) (4) (6) (7) (23)
’20 (3) (4) (4) (5) (17)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 0 1 0 0 0 0 0 0 1 1 1 +5.0% 0 0 0 (21.4%)
Gross margin, % (354.08) (258.41) (57.92) 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 +454.1 pt
EBT (39) (25) (16) (16) (19) (28) (39) (41) (45) (46) (40) +1.8%
EBT margin, % (10,286.99) (4,928.12) (4,351.36) (6,710.63) (5,275.14) (7,880.50) (10,026.94) (8,492.01) (6,651.68) (7,732.04) (7,884.06) +2,554.9 pt
Net income (39) (25) (16) (16) (19) (28) (39) (41) (45) (46) (40) +1.8%
Per share, $
Per share, $ Revenue 0.91 1.05 0.16 0.04 0.02 0.01 0.01 0.01 0.01 0.01 0.01 (40.2%)
Earnings (93.62) (51.85) (8.26) (2.80) (1.08) (0.73) (0.89) (0.93) (0.95) (0.69) (0.60) (42.0%)
Cash flow (74.08) (48.30) (5.66) (2.22) (0.78) (0.59) (0.78) (0.69) (0.79) (0.57) (0.60) (41.8%)
Capex (1.97) (0.21) 0.01 (0.01) (0.01) (0.01) (0.02) (0.01) 0.00 0.00 0.00 (58.6%)
Free cash flow (76.05) (48.51) (5.65) (2.23) (0.79) (0.60) (0.80) (0.70) (0.79) (0.57) (0.60) (42.0%)
Book value 47.18 13.50 4.33 1.22 6.14 3.60 2.44 1.56 1.74 0.68 0.39 (37.6%)
Shares, m 0 0 2 6 21 39 44 45 48 67 68 +75.7%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 162.28 20.95 31.91 42.15 1,026.07 653.40 167.17 140.07 302.78 316.73 105.02 286.4
P/B 3.13 1.63 1.20 1.41 2.93 1.67 0.61 0.98 2.49 4.14 2.01 2.0
EV/Sales 106.24 32.44 38.31 8.85 672.05 265.07 (101.89) (10.36) 170.52 220.79 39.84 140.2
EV/FCF (1.27) (0.70) (1.10) (0.16) (14.83) (4.06) 1.13 0.16 (3.08) (3.45) (0.49) (2.7)
Cash, $m
Cash, $m Operating cash flow (31) (23) (13) (13) (16) (23) (34) (31) (38) (38) (41) +2.3%
Capex (1) 0 0 0 0 0 (1) (1) 0 0 0 (27.8%)
Free cash flow (32) (23) (13) (13) (17) (23) (35) (31) (38) (38) (41) +2.0%
Balance, $m
Balance, $m Working capital 31 6 10 7 127 140 103 67 82 44 25 +3.8%
Net debt (21) (7) (11) (10) (131) (141) (105) (75) (92) (58) (35) +11.8%
Shareholders’ equity 20 7 10 7 128 140 106 70 83 45 27 +9.7%
Returns, %
Returns, % ROA (67.99) (88.67) (145.55) (122.58) (30.58) (19.92) (29.15) (41.92) (50.84) (57.68) (70.89) +10.3 pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 (2,317.73) 0.00 0.00 0.00 0.00 0.0 pt
ROE (114.59) (189.78) (232.13) (192.08) (33.36) (21.09) (31.39) (47.10) (59.54) (71.49) (94.14) +43.1 pt
People
People Employees 53 17 13 14 12 23 26 32 33 31 — (5.8%)
Revenue/emp, $m 0.01 0.03 0.03 0.02 0.03 0.02 0.01 0.02 0.02 0.02 — +11.5%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Cardiff Oncology, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CSBR Champions Oncology, Inc. $66.3M — (loss-making) — (loss-making) +8.84% (above 0%: growing) n/m −198.74% (below 0%: shrinking) 50.54% (2.69%) Compare
CNXU Conexeu Sciences Inc. $65.4M — (loss-making) — — n/m −1,084.33% (below 0%: shrinking) — 0.00% Compare
CING Cingulate Inc. $61.7M — (loss-making) — — n/m −24.28% (below 0%: shrinking) 0.00% 0.00% Compare
FBIO Fortress Biotech, Inc. $61.4M 0.6× 0.8× +14.04% (above 0%: growing) n/m −115.37% (below 0%: shrinking) 67.18% (53.46%) Compare
TENX Tenax Therapeutics, Inc. $61.0M — (loss-making) — −77.98% (below 0%: shrinking) n/m −125.93% (below 0%: shrinking) 0.00% 0.00% Compare
CGTX Cognition Therapeutics, Inc. $60.4M — (loss-making) — — n/m +45.35% (above 0%: growing) 0.00% 0.00% Compare
CRDF Cardiff Oncology, Inc. $58.8M — (loss-making) — (loss-making) −14.05% (below 0%: shrinking) n/m −41.36% (below 0%: shrinking) 100.00% (9,245.19%)
TELO Telomir Pharmaceuticals, Inc. $57.5M — (loss-making) — — n/m −45.34% (below 0%: shrinking) — 0.00% Compare
CRBP Corbus Pharmaceuticals Holdings, Inc. $55.3M — (loss-making) — (loss-making) −92.09% (below 0%: shrinking) n/m −78.52% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $61.2M — — −34.57% — −96.94% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 26 August 2026

Ownership

Directors and executive officers, together 8.80%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Cardiff Oncology, Inc. (CRDF) Latest News

27 Oct

Impact 3 · · GlobeNewswire

21 Oct

Impact 3 · · GlobeNewswire

17 Aug

Impact 3 · earnings

11 Aug

Impact 3 ·

15 Jul

Impact 3 ·

30 Jun

Impact 3 ·

22 Jun

Impact 4 · · Zacks Small Cap Research

2 Jun

Impact 4 · · GlobeNewswire

22 May

Impact 3 · · Zacks Small Cap Research earnings

21 May

Impact 4 ·

14 May

Impact 3 · · GlobeNewswire

27 Apr

Impact 3 · · GlobeNewswire

21 Apr

Impact 4 ·

6 Apr

Impact 3 · · Zacks Small Cap Research

25 Mar

Impact 4 · · MarketBeat

20 Mar

Impact 3 · · GlobeNewswire

26 Feb

Impact 4 · · MarketBeat

24 Feb

Impact 3 · · Associated Press Finance
Impact 3 · · GlobeNewswire

3 Feb

Impact 4 · · Zacks Small Cap Research

29 Jan

Impact 3 · · Simply Wall St.Simply Wall St.MT NewswiresZacksSimply Wall St.MT NewswiresSimply Wall St.Insider Monkey

27 Jan

Impact 4 · · MarketBeat
Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire

22 Jan

Impact 4 · · Simply Wall St.

22 Dec

Impact 3 · · Simply Wall St.

10 Dec

Impact 3 · · Simply Wall St.

9 Dec

Impact 4 · · Zacks Small Cap Research

8 Dec

Impact 4 · · GlobeNewswire

24 Nov

Impact 3 · · GlobeNewswire
stockrow.com/CRDF · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com